[ad_1]
Healthcare agency Vertex Prescribed drugs Included (NASDAQ: VRTX) on Monday reported a decline in adjusted earnings for the primary quarter, regardless of a rise in revenues.
Complete revenues elevated to $2.37 billion within the first quarter from $2.10 billion within the corresponding interval of 2022. For the complete fiscal yr, the administration expects product revenues to be between $9.55 billion and $9.70 billion.
In the meantime, adjusted earnings dropped to $3.05 per share within the March quarter from $3.52 per share within the prior-year interval. Unadjusted revenue was $699.8 million or $2.69 per share, in comparison with $762.1 million or $2.96 per share final yr.
Prior Efficiency
[ad_2]
Source link
